Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06968169 · ClinicalTrials.gov registry record · NA

The Short-term Verbal Memory Endophenotype for Developmental Language Disorder Language Disorder

A NA study of Healthy Subjects and Developmental Language Disorder, sponsored by Father Flanagan's Boys' Home.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06968169 is a NA study of Healthy Subjects and Developmental Language Disorder that is actively recruiting participants, run by Father Flanagan's Boys' Home. The registered enrollment target is 120 participants, roughly in line with the 127-participant average among 69 other Healthy Subjects trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06968169, a NA study of Healthy Subjects and Developmental Language Disorder, is actively recruiting participants, sponsored by Father Flanagan's Boys' Home.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to determine how memory and attention affect the ability of children with developmental language disorder (DLD) to learn and use new vocabulary.

Interventions

  • BEHAVIORAL Supportive learning
  • BEHAVIORAL Cascades

Study Locations (1)

Nebraska

  • Boys Town National Research Hospital - Omaha

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-02-09
Est. Completion 2030-06
Phase NA

Sponsor

Father Flanagan's Boys' Home

16 total trials

What the Registry Record Tells You About NCT06968169

The ClinicalTrials.gov registry entry for NCT06968169 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 127-participant average among 69 other Healthy Subjects trials with a reported enrollment target. The listed sponsor is Father Flanagan's Boys' Home, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Supportive learning is the first listed.

NCT06968169 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT06968169 about?

NCT06968169 is a clinical study titled "The Short-term Verbal Memory Endophenotype for Developmental Language Disorder Language Disorder". The goal of this clinical trial is to determine how memory and attention affect the ability of children with developmental language disorder (DLD) to learn and use new vocabulary.

What is the current status of trial NCT06968169?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-02-09. Estimated completion is 2030-06.

What conditions does trial NCT06968169 study?

This clinical trial studies the following conditions: Healthy Subjects, Developmental Language Disorder.

What interventions are being tested in trial NCT06968169?

The interventions under investigation include: Supportive learning (BEHAVIORAL), Cascades (BEHAVIORAL).

Who is sponsoring clinical trial NCT06968169?

This trial is sponsored by Father Flanagan's Boys' Home, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06968169 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Subjects

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.